What are the side effects of HealthdirectFree Australian health advice you can count on.?

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme

Does HealthdirectFree Australian health advice you can count on. interact with other medications?

Trametinib should be avoided with: CYP3A4 and CYP2C8 inducers or inhibitors when it is used along with dabrafenib.

Can HealthdirectFree Australian health advice you can count on. be used during pregnancy?

( AHT ) For the active ingredient trametinib You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

What precautions should be taken with HealthdirectFree Australian health advice you can count on.?

•Do not use the drug if you are planning to become pregnant as trametinib may cause harm to the fetus. Monitor blood glucose levels while taking trametanib as the drug is capable of causing high blood sugar level. Blood pressure should be checked from time to time as tramatenib can cause hypertension. Trametanib may cause fertility problems. It should be avoided by women of child bearing age.

HealthdirectFree Australian health advice you can count on.

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

( ARTG ) Unresectable or metastatic melanoma,MEKINIST in combination with dabrafenib is indicated for the treatment of patients with BRAF V600 mutation positive unresectable Stage III or metastatic (Stage IV) melanoma.,MEKINIST as a monotherapy is indicated for the treatment of patients with BRAF V600 mutation positive unresectable Stage III or metastatic (Stage IV) melanoma and in whom either there is intolerance to BRAF inhibitors or BRAF inhibitors cannot be used.,MEKINIST as monotherapy has not demonstrated clinical activity in patients who have progressed on BRAF inhibitor therapy (see section 5.1 Clinical Trials).,Adjuva‍‍‍‍‍‍‍nt treatment of melanoma,MEKINIST in combination with dabrafenib is indicated for the adjuvant treatment of patients with melanoma with a BRAF V600 mutation and involvement of the lymph node(s), following complete resection.,Anaplastic thyroid cancer (ATC),MEKINIST in combination with dabrafenib is indicated for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with a BRAF V600 mutation and with no satisfactory locoregional treatment options.,Non-small cell lung cancer (NSCLC),MEKINIST in combination with dabrafenib is indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.,Low-grade glioma,Mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy (see section 5.1 Clinical studies).,High-grade glioma,Mekinist in combination with dabrafenib is indicated for the treatment of paediatric patients 1 year of age and older with high-grade glioma (HGG) with a BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options (see section 5.1 Clinical studies).

HealthdirectFree Australian health advice you can count on.

User Reviews